We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
It was based on evidence from clinical trials that demonstrated that subcutaneous administration of immunoglobulin has been shown to decrease the rate of infections in patients with SID.